Aeon 的最新消息
@edyong209 Yeah okay.
2019
https://www.weforum.org/agenda... https://t.co/DLHCyaytDI
@edyong209是的,好的。
2019
https://www.weforum.org/agenda...对不起,对不起。https://t.co/DLHCyaytDI
@OmicronData Very true, but the question is how little can be be used without eliminating a lot of the benefit. 1-2% of infections is already pretty narrow, and likely underused, not overused, relative to benefit. Focusing on WHO is getting it likely more important than HOW MANY.
@OmicronData非常正确,但问题是,在不消除许多好处的情况下,可以使用的内容有多少。相对于效益而言,1-2%的感染已经相当有限,而且可能使用不足,而不是过度使用。关注世界卫生组织得到的可能比多少更重要。
@OmicronData Now there is a very good question whether then 20k getting it are actually the 20k who would most benefit (as opposed to well off and well served, which perhaps 'some' risk) and that is mostly likely a very strong no (but we don't really know).
@OmicronData现在有一个很好的问题,那就是20k获得它的人是否真的是20k中受益最多的人(而不是富裕和服务周到的人,这可能“有些”风险),这很可能是一个非常强烈的否定(但我们真的不知道)。
@OmicronData 1. The number of cases is way understated, this is not even close to 12%, might be closer to 1-2%.
2. The criteria for 'high risk' are not strict. It's only in the youngest and healthiest that trial didn't show a clear benefit (but did show weak indiciation of benefit).
@OmicronData 1。病例数量被低估了,甚至不接近12%,可能接近1-2%。
2、“高风险”的标准不严格。只有在最年轻和最健康的人群中,试验才没有显示出明显的益处(但确实显示出微弱的益处迹象)。